CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Autotitrating Positive Airway Pressuredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00804349
NCT00804349Phase 4Completed

Apnea Rampant In Acute Decompensated Heart Failure II

Albert Einstein Healthcare Network·interventional·Posted Dec 8, 2008·Updated Mar 9, 2020

In Brief

A Phase 4 clinical trial evaluating Autotitrating Positive Airway Pressure for Heart Failure and Sleep Apnea Syndromes. Completed, enrolled 6 participants across 1 site.

Detailed Summary

Heart Failure affects 5-6 million Americans and there are about 550 thousand new cases of heart failure every year. There are approximately 3 million hospital admission for acute decompensated heart failure with hospital readmission rate of 20% at 30 days and 50% at 60 day, costing up to 20 billion dollars per year. In our previous study we have discovered that sleep disordered breathing is prevalent in 70% of patients with acute decompensated heart failure. We hypothesize that, detection and treatment of sleep disordered breathing in acute decompensated heart failure patients will reduce episodic hypoxic events during acute decompensation and may decrease hospital length of stay and reduce future readmissions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNexan Inc

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 8, 2008
Enrollment StartOct 1, 2008
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.6 years ago

Interventions

Autotitrating Positive Airway Pressuredevice

Patients will be treated with Autotitrating Positive Airway Pressure therapy